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Department of Dermatology, Binnengasthuis, University of Amsterdam, Amsterdam, The Netherlands 
Most immunologic diseases are caused by the derailment of the humoral or cellular 
pathways of the immunologic defense system. This derailment results from numerous factors 
such as the inability of the patient to remove the pathogen; the consumption, defect, or 
deficiency in any component of these pathways, and the overproduction of any of the 
components. 
To diagnose these immunologic disorders one has to detect the pathogen and the reactions 
caused by it and to determine the cause of its nonclearance. The immunofluorescence 
technique has been invaluable in detecting both the antigen that causes the disease and the 
reactions initiated by the antigen, such as the production of antibodies and the activation of 
the complement system. The immunoperoxidase technique has also been used for these 
purposes in certain instances. For detecting the circulating immune complexes which occur 
as intermediates in the chain of reactions initiated by the antigen, various physicochemical 
and biologic techniques have been used. However, none of these tests seems to be totally 
reliable for determining whether circulating immune complexes are present. 
The consumption of complement was detected by hemolytic estimations and radial 
immunodiffusion or rocket electrophoresis. These techniques were also useful in detecting the 
hereditary deficiencies in immunoglobulins and components of classical and alternative 
pathways of complement activation. Since these techniques cannot be used to estimate IgE, 
the radioallergosorbent test was used to measure such levels in atopic patients. 
Cellular hypersensitivity was detected with skin tests together with methods which assess 
the ability of lymphocytes to produce mediators in response to antigen. Many of these media-
tor assays, however, are not suitable for this purpose. A satisfactory substitute appears to be 
to determine the factor in antigen-stimulated, lymphocyte culture supernatants which acti-
vates macrophages to take up radiolabeled colloidal gold or radiolabeled glucosamine. In con-
tact allergic dermatitis, an increase in the IgD-bearing lymphocytes and granulocytes has also 
been correlated with cellular hypersensitivity. Lymphocytes and polymorphonuclear leuko-
cytes coated with antibodies mainly directed against nuclear antigens of the basal layer cells 
of the noninvolved epidermis have invariably been encountered in psoriasis. The use of these 
findings for diagnostic purposes and for understanding the mechanisms of certain diseases is 
being explored. 
The factors that cause the various immunologic 
diseases in man can be broadly divided into four 
categories: (1) self antigens; (2) foreign antigens 
such as viruses, bacteria, chemicals, and drugs 
which may form immunogens with body proteins; 
(3) foreign substances such as bacterial polysac-
charides; and (4) immunodeficiencies and other 
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Abbreviations: 
ECF-A: eosinophil chemotactic factor of anaphylaxis 
FTC: fluorescein thiocyanate 
LPF: lymphocyte proliferation factor 
MAF: macrophage activator factor 
MIF: migration inhibition factor 
MNLCTX: mononuclear chemotactic factor 
PG: prostaglandin 
PMN: polymorphonuclear 
RAST: radioallergosorbent test 
SRS-A: slow-reacting substance of anaphylaxis 
genetic abnormalities. These factors can cause 
derailment of the humoral or cellular pathways of 
immunologic reactions. Figure 1 shows the main 
humoral immunologic reactions but not the side 
reactions, such as abnormalities in the mechanism 
of blood coagulation caused by the activation of 
alternative pathway of complement activation. 
In normal individuals, these reactions appear to 
be inhibited by agents in the blood, but they could 
be activated by'factors such as endotoxins or by an-
tigens if antibodies have already been produced. 
After the source of their activation is removed, they 
return to the unactivated state. In a disease state, 
some of these reactions are activated, depending 
on whether the activator is an antigen or an endo-
toxin, and remain so during the course of the dis-
ease either because the activator is continuously 
resupplied or because the patient's reticuloendo-
thelial system or some other eliminating mecha-
nism is unable to remove it. Other causes of disease 
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FIG. 1. Summary of main humoral immunologic reactions in clinical hypersensitivity and disease. Ag = antigen, 
Ab = antibody, CI-C9 = components of complement, IF = initiating factor, P = properdin, C3PA = C3 proactivator, 
C3PAase = C3 proactivator convertase. 
states include a defective component of these path-
ways, e.g. , a deficient inhibitor of the first compo-
nent of complement in hereditary angioneurotic 
edema and the overproduction of IgE in atopic pa-
tients. 
First, we shall describe these pathways briefly. If 
antibodies have been produced by an antigen, 
addition of more antigen may lead to the formation 
of antigen-antibody complex. This complex may 
be fixed or circulating depending on whether the 
antibodies have been produced against a fixed 
antigen such as autoantigen or whether the antigen 
is circulating or is one of the proteins of the 
circulatory system. If the complex is circulating 
and large ( > 198), it will be deposited between the 
endothelial cells in such a way [1] that a platelet-
activating factor is released from IgE-sensitized 
basophils by immune complexes and the vasoac-
tive amines are released by the platelet-activating 
factor. Because of increased vascular permeability, 
larger complexes are trapped in and around the 
wall of the blood vessel. 
Whatever the mechanism of deposition, the im-
mune complexes either before or after deposition 
can activate the complement sequence that leads 
to the generation of chemotactic factors and is fol-
lowed by the attraction of polymorphonuclear 
(PMN)-leukocytes, the lysosomal enzymes of which 
may cause tissue injury [2]. 
If the alternative pathway has been activated, 
say by endotoxin, complement from the C3 stage 
will be activated by a mechanism described by 
Muller-Eberhard [3], which involves an initiating 
factor, properdin, C3 proactivator, C3 proactivator 
convertase, C3, and probably unknown proteins of 
this pathway. After complement from C3 has been 
activated, the remaining steps of complement 
action leading to tissue injury and membrane 
attack are common to both pathways. 
In addition to the mechanism that activates the 
complement system, there are other causes of 
allergic disorder in atopic patients, i.e., IgE anti-
bodies which combine with mast cells through Fc 
fragments. When allergen reacts with cell-bound 
IgE, the enzyme sequence is activated and such 
chemical mediators as histamine, the slow-react-
ing substance of anaphylaxis (8R8-A), prosta-
glandins (PGs), eosinophil chemotactic factor of 
anaphylaxis (ECF -A), and kallikrein are released. 
The cellular pathways of self-defense involve 
various cell types. One of them, the B-Iymphocyte, 
is the immunoglobulin-bearing lymphocyte found 
in lymph nodes. The other cell, the T -lymphocyte, 
is the monocyte which originates in the bone 
marrow, is processed in the thymus, and is devoid 
of antibody. At least these two types are needed to 
express cellular hypersensitivity. When sensitized 
lymphocytes come in contact with antigen, they 
release several proteins, such as the migration 
inhibition factor (MIF), the skin reactive factor, 
and about 10 more which have a pronounced effect 
on other cells involved. These factors, perhaps by 
autocatalytic or positive feedback effect, help to 
produce biologic activities from nonsensitized 
lymphocytes as well. By virtue of their different 
properties, they lead to the localized accumula-
tion of nonspecific inflammatory mononuclear cells 
and, in extreme reaction, to tissue necrosis (see 
detailed descriptions by Lawrence and Lardy 
[4), David [5), and Asghar and Cormane [6]) . 
Both humoral and cellular immunologic path-
ways may be operative at the same time in a 
patient or an experimental animal. Besides their 
activation by certain pathogens, some genetic 
deficiency, defects or overproduction may eventu-
ally impair the function of the whole pathway and 
may cause the disease. 
We have described these pathways briefly be-
cause our aim is not to discuss the mechanisms of 
immunologic reactions but to show that the 
method of diagnosing immunologic disorders 
should be based on either a recognition of the 
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factors that are responsible for initiating the dis-
ease or the detection of reactions which have been 
activated by these factors. Thus, the diagnosis of 
immunologic diseases should be based on the 
criteria described in Table 1. 
DETECTION OF ANTIGEN 
In an immunologic reaction caused by an anti-
gen, microprecipitation of antigen and antibodies 
may occur in and around the blood vessel walls or 
immune complexes may be found in the circulation 
before they have been deposited. So far, there is a 
scarcity of data showing antigen parts of immune 
complexes which are circulating, but in certain 
cases the immunofluorescence technique has been 
used to demonstrate the antigen in the deposited 
immune complexes. The rationale and the techni-
cal details of the immunofluorescence technique 
have been described by Beutner et al [7], and the 
requisites for achieving peak performance with 
immunofluorescence microscopy have already 
been discussed by Ploem [8]. 
Using this technique, Wemambu et al [9] found 
evidence that microbacterial antigen is the cause 
of the Arthus-like reaction in a form of leprosy 
characterized by neutrophil infiltrates. Parish [10] 
demonstrated Streptococcus pyogenes group A and 
D antigens in cutaneous vasculitis and erythema 
nodosum. Streptococcal, candidal, and microbac-
terial antigens were also detected in the lesions of 
vasculitis. 
Simultaneous staining for the immunoglobulins 
TABLE I. Basis of diagnosis various immunologic disorders 
1. Detection of antigen 
2. Detection of antibod-
les 
3. Detection of immune 
complexes 
4. Involvement of com-
plement by classical 
or alternate pathway 
5. Immunodeficiencies 
and other genetic ab-
normalities 
Detection of cellular 
hypersensitivity and 
studies of ancillary 
cells 
Whether fixed, circulating, 
self or foreign. Identifica-
tion if possible. 
Whether locally fixed, cir-
culating, or on the sur-
face of ancillary cells. 
Whether circulating or 
fixed. 
Whether complement is ac-
tivated locally or sys-
temically. Whether com-
plement levels are altered 
and fragments detecta-
ble. 
Whether there is deficiency 
or genetic defect in im-
munoglobulins, comple-
ment components of clas-
sical or alternative path-
way, or inhibitors of 
these systems. 
Whether delayed hyper-
sensitivity is operative. 
Whether antibodies di-
rected against a particu-
lar antigen are present on 
ancillary cell surface. 
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and bacterial antigens with rhodamine and fluores-
cein thiocyanate (FTC}-labeled antisera occasion-
ally revealed them in combination. Parish [10] has 
also demonstrated the antibody specificity of im-
munoglobulins against the antigen in the lesion. 
The extracellular isolated protein antigen of Strep. 
pyogenes group A and antigen extracted from 
Staphylococcus aureus were unequivocally fixed on 
aggregated IgG in the lesions. 
The immunofluorescence technique is now es-
tablished as a diagnostic and investigative tool in 
immunodermatology. Another technique, which 
uses other markers, is the immunoperoxidase tech-
nique in which peroxidase-coupled antibody reacts 
with antigen and the colored enzyme product 
serves as a stain. Although this technique is not as 
sensitive as the immunofluorescent technique [11], 
it is useful for certain purposes in light and in 
electron microscopy [12]. 
DETECTION OF ANTIBODIES 
Direct and indirect immunofluorescence tech-
niques have been useful in detecting antibodies, 
both fixed and circulating. Several antibodies 
under different pathologic conditions have been 
detected by this technique, but only the most 
important are listed in Table II. 
Antibodies may also occur on the surface of cells 
such as lymphocytes or PMN-Ieukocytes (see 
below). 
DETECTION OF IMMUNE COMPLEXES 
The mechanism of circulating immune complex 
disease is the same as that of fixed complexes 
except that active processes are involved in the 
deposition of immune complexes. The persistent 
presence of complexes can cause such pathologic 
effects as anaphylaxis, Arthus-like reaction, granu-
lomata, and hyperviscosity. Immunofluorescence 
microscopy is now indispensable for detecting 
deposited immune complexes. The circulating 
complexes can be detected by various physico-
chemical and biologic methods (Tab. III). 
Physicochemical Methods 
The physicochemical methods depend on the 
separation of complexes from serum immunoglob-
ulins because of size, charge, or solubility charac-
teristics. Analytical ultracentrifugation has been 
used to demonstrate 22S IgG-IgM complexes in 
the serum of patients with rheumatoid arthritis 
TABLE II. Antibodies detectable in the skin and/or serum 
by immunofluorescence technique in various diseases 
Substrates for antibodies 
Subcellular constituents 
Stratum corneum 
Intercellular space material 
Basal cell cytoplasm a and 
membrane 
Basement membrane 
Diseases 
SLE 
Psoriasis vulgaris 
Pemphigus, burns 
Drug reaction 
Pemphigoid 
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TABLE III . Methods employed for the detection of 
circulating immune complexes 
Physicochemical methods 
Analytical ultracentri-
fugation 
Density gradient ultra-
centrifugation 
Electron microscopy 
Cryoprecipitation 
Differential solubility 
Biologic methods 
Reaction with Clq 
Reaction with rheumatoid 
factor 
Platelet aggregation 
Histamine release from 
guinea-pig lung 
Increased antibody con-
centration after de-
struction of antigen 
Anticomplementary 
activity 
and 11-13S IgG-IgG complexes in the serum of 
W aldenstrom 's benign hypergammaglobulinemic 
purpura [13]. This technique, however, is useful 
only for detecting large quantities of circulating 
complexes (>5% of total serum proteins). Other 
complexes can be detected by density gradient 
centrifugation. Immune complexes in the sediment 
have been visualized by electron microscopy [14]. 
Other methods of detecting immune complexes 
take advantage of the fact that the latter have 
decreased solubility at 4 ec, at low ionic strength, 
or in salting-out conditions. These approaches 
have, however, been unsatisfactory for several 
reasons, including the fact that under these condi-
tions many unwanted proteins, such as antibodies 
with rheumatoid factor activity and Clq, tend to 
precipitate. 
Biologic Methods 
Several biologic methods have been used to 
detect circulating immune complexes. C1q has 
been used to detect immune complexes because it 
can precipitate with them in agarose gel. Asghar, 
Faber, and Cormane [15], however, have shown in 
the serum of a patient with allergic vasculitis that 
C1q gave a strong precipitation line with some 
unidentified material which could not be shown to 
be an immune complex. Similarly, precipitation of 
complexes by isolated monoclonal rheumatoid fac-
tors may give a false positive reaction. 
A comparatively more sensitive and reproduci-
ble procedure for detecting soluble immune com-
plexes has been reported [16]. Radiolabeled C1q is 
reacted with sera containing immune complexes. 
Both free and complex bound (1251) Clq are sepa-
rated by selective precipitation with polyethylene 
glycol. Complex bound radioactivity is the mea-
sure of immune complexes. This method is more 
sensitive than agarose gel precipitation but may 
have similar drawbacks of reaction with nonim-
mune Clq reactants. In addition, the different Clq 
levels in serum samples might have some effect 
since higher C1q levels may cause more competi-
tion with radioactive C1q than lower levels. More 
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work is needed to confirm the suitability of this 
method for immune complex detection. 
Immune complexes were detected by virtue of 
their property to release histamine from guinea-pig 
lungs [17] and to aggregate platelets [18]. When 
antigen is known to be in complexes, an increase in 
free antibody concentration after enzymic degra-
dation of antigen suggests the presence of immune 
complexes. DNA-anti-DNA complex has been de-
tected by this method [19]. 
Decreased levels of total complement or a spe-
cific component of complement (C3) associated 
with the degradation products of complement (~lC 
- ~lA + a2D) have been used to measure circulat-
ing immune complexes. Recent data on the alter-
native pathway, however, suggest that these obser-
vations implicate a nephritic factor or the activa-
tion of the alternative pathway at any other step 
[3 ]. 
Thus, these biologic tests do not conclusively 
identify the immune complexes circulating at any 
one time. Several factors affect the accuracy of 
these tests: the degree of lattice formation required 
to initiate the biologic test reaction, the excess of 
antigen or antibody in the sera at the time of 
testing, pseudoimmune complexes which behave 
like them, and the immunoglobulin class of anti-
bodies in complexes. No current technique can 
demonstrate the presence or absence of immune 
complexes. Perhaps some of these techniques, both 
physicochemical and biologic, should be combined 
but such a combination would be too cumbersome 
for routine diagnoses. Further research is obviously 
needed. 
INVOLVEMENT OF COMPLEMENT BY CLASSICAL OR 
ALTERNATIVE PATHWAY 
If fluorescent antibodies directed against the in-
dividual components of the classical or alternative 
pathway are used, the binding of these components 
at the site of the lesions can be followed. This 
technique, which does not differ from that used to 
detect antigen or antibody, can be used with 
FTC-labeled antisera to any of the complement 
components. Immunofluorescence has been espe-
cially useful with anti-C3 since C3 is present in the 
immunologic lesions in largest amounts. C4, C5, 
and Clq have also been detected in lesions. In all of 
the diseases listed in Table III concomitant deposi-
tion of complement has been observed. Deposition 
of properdin and C3 proactivator have been ob-
served in kidney biopsies of systemic lupus ery-
thematosus (SLE) nephritis, chronic membrano-
proliferative glomerulonephritis, and other dis-
eases [20], but such data with these or other 
components of alternative pathway are scarce in 
skin diseases. 
Evidence of in vivo complement activation by 
either of the pathways is the detection of fixed 
components, decreased levels of the components 
of alternative or classical pathway, and the forma-
tion in vivo of breakdown products of components 
of these pathways. These phenomena have been 
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studied in detail only with regard to total hemolytic 
complement and C3. a 2D, in particular, is found in 
the circulation of patients with hypocomplemen-
temic membranoproliferative glomerulonephritis. 
Occasionally in other immune disorders (e.g., 
hypocomplementemic SLE), C3 breakdown has 
been observed [21]. Additional research into other 
skin diseases will probably yield more information. 
Total hemolytic activity in the serum can be 
measured by estimating the degree of hemolysis of 
sensitized sheep erythrocytes caused by various 
dilutions of test serum [22]. The individual com-
ponents can also be estimated by hemolytic meth-
ods which have clearly been described by Lach-
mann, Hobard, and Aston [23]. Several hemolytic 
methods can also estimate the alternative pathway 
as well as its components. Alternatively, the levels 
of these components or their breakdown products 
can be determined antigenically [24,25]. A sample 
is introduced in the holes at the bottom of the gel 
which contains monospecific antiserum. The gel 
plate is allowed to stand, as in the Mancini tech-
nique, or electrophoresed. The area of ring or the 
height of the precipitate is the measure of antigen 
concentration or, in this case, of the concentration 
of component of these pathways. 
IMMUNODEFICIENCIES AND OTHER GENETIC 
ABNORMALITIES 
The term immunodeficiency encompasses a 
broad spectrum of abnormalities in the host de-
fense that ranges from mild to severe and is 
paralleled by increasing susceptibility to different 
pathogens. Hereditary deficiencies in immuno-
globulins, complement components, inhibitors of 
complement system and the constituents of PMN-
leukocytes, as well as B- and T-cell function, have 
been reported. These deficiencies can easily be 
tested by the techniques already. described. De-
ficiencies in B-cell and T-cell -function can be de-
tected by assaying such functions as antibody and 
MIF production. 
In those patients who are only functionally 
deficient in a particular protein, the protein may 
be defective or have impaired biologic activity; for 
example , the defective C1-esterase inhibitor in 
hereditary angioneurotic edema and the defective 
IgA in some cases of atopy. In such cases, the 
protein is estimated according to its activity as 
well as antigenically. These activities are too 
nUmerous and diverse to allow us to describe how 
the activities of the components of the defense 
system are determined. Some of the immunodefi-
ciencies and genetic defects, together with the 
diseases with which they are associated, are listed 
i.n Table IV. 
Finally, the' techniques described so far do not 
detect another defect, not in the structure, but in 
:he quantity of production. This is the higher levels 
)f IgE in atopic patients. Diagnosis in vitro based 
m IgE levels is becoming a routine analytical 
Jrocedure in many laboratories. The radio aller-
;osorbent test (RAST) [25] seems to be the most 
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TABLE IV. Some examples of genetic immunologic 
deficiencies and the defects associated with disease states 
Disease Deficiency 
Wiskott-Aldrich Syndrome Deficiency in T-cell 
function 
Some forms of chronic Deficiency in T-cell 
mucocutaneous candidiasis function 
Some cases of atopy and Defect in or deficiency 
a range of disorders of IgA 
Hereditary angioneurotic Defect in or deficiency 
edema of Cl-esterase inhibitor 
Arthritis of sex-linked Gammaglobulin deficiency 
agammaglo bulinemia 
Lupus-like illness C2 deficiency 
suitable large-scale test for IgE antibody. The 
rationale of this technique is that when allergen 
bound to an insoluble matrix such as cellulose is 
incubated with test serum, allergen-polymer-IgE 
complex is formed. Radioactive anti-IgE can com-
bine with this complex, and the radioactivity in 
the insoluble matrix gives the amount of IgE 
present in the serum. 
DETECTION OF CELLULAR HYPERSENSITIVITY AND 
STUDIES OF ANCILLARY CELLS 
Many authorities still regard skin tests as the 
only valid measure of cutaneous delayed hypersen-
sitivity. Several studies, however, report that 
many assays of cellular hypersensitivity in vitro 
are equally good procedures. These assays are 
based on evaluating the ability of lymphocytes to 
produce mediators after antigen challenge or chal-
lenge with immunologic equivalent. They include 
the tests of release of (1) lymphocyte proliferation 
factor (LPF), (2) migration inhibition factor 
(MIF), (3) macrophage activator factor (MAF) , 
and (4) mononuclear chemotactic factor 
(MNLCTX). 
Some of these methods have drawbacks. Since 
antigen-induced proliferation of lymphocytes can 
occur without delayed hypersensitivity or with 
Arthus reaction, measuring LPF is not necessarily 
an expression of delayed-type hypersensitivity . As 
far as using the ability of lymphocytes to produce 
MIF to test delayed hypersensitivity is concerned, 
despite various technical modifications, the pro-
longed multistep procedures are subjeCt to numer-
ous technical problems; hence there is considerable 
variation within and between assays. In addition, 
competing molecular entities in the supernatant 
fractions which enhance macrophage migration, 
plus the fact that B-cell products such as anti-
bodies can inhibit macrophage migration, make it 
hard to believe that the MIF assay really correlates 
with delayed hypersensitivity. Similarly, the tech-
nique which involves assaying MNLCTX can be 
complicated by the products of complement fac-
tors such as C5a. Furthermore, both T-cell and 
B-cell mitogens stimulate T -cells to produce 
MNLCTX. Even nonmitogenic substances which 
interact with B-cell membranes such as anti-
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immunoglobulins, C3 sites, and antigen-antibody 
complexes are all potent activators of B-cell 
MNLCTX production [26]. 
Some investigators have advocated alternative 
mediator assays, namely, MAF [27]. Antigen-
stimulated lymphocyte culture supernatants con-
tain a factor which causes macrophages to take up 
radiolabeled colloidal gold. This assay is quantita-
tive, rapid, and sensitive, but gold particles must 
not be allowed to aggregate; otherwise phagocyto-
sis occurs and gives a nonspecific result. Another 
assay for macrophage activation which uses the 
uptake of radiolabeled glucosamine has been de-
scribed. 
Direct immunofluorescence studies of biopsies 
taken from positive patch tests elicited by various 
antigens in our laboratory revealed lymphocytes 
with membrane-bound immunoglobulins through-
out the dermis and epidermis, particularly in and 
around the blood vessel walls [28]. With the 
immunofluorescence technique, we found immu-
noglobulins and complement-bearing leukocytes 
and lymphocytes in the lesional skin of specimens 
of patients with various dermatoses [28,29]. In all 
the cases of allergic contact dermatitis examined, 
the percentage of IgD-bearing lymphocytes and 
PMN -leukocytes was increased. This altered ratio 
of circulating B-cells and T -cells may indicate an 
impaired cooperation of at least these cell popula-
tions. Like lymphocyte populations, the PMN-
leukocyte populations consist of cells with and 
without immunoglobulins on the cell membrane in 
the same ratio as in healthy controls. 
Another finding observed by the immunofluores-
cence technique was the occurrence of antibodies 
in eluates of lymphocytes and PMN -leukocytes 
obtained from 5 untreated psoriasis patients [30]. 
These antibodies appeared to be directed mainly 
against the nuclei of the basal cell layer (Fig. 2); 
however, antibodies directed against the nuclei of 
epidermal and dermal cells have also been seen. 
Since the eluted antibodies are directed mainly 
against nuclear antigens of dividing epidermal 
cells and not against the nuclei of all cells, it may 
be that the nuclear antigens are the nonhistone 
proteins which regulate the growth of the dividing 
epidermal cells [31]. 
The lymphocyte eluates of 3 patients with dis-
coid lupus erythematosus and 2 with pemphigoid 
contained IgG antibody reactive with normal 
human skin or guinea-pig basement membrane. 
Similarly, lymphocyte eluates from a patient with 
pemphigus contained IgG antibody reactive with 
intercellular substances of monkey esophagus, and 
those of a patient with a drug reaction contained 
antibody reactive with basal cells of stratified 
epithelium_ [32]. These results may prove espe-
cially useful in diagnosing diseases associated with 
cellular hypersensitivity. 
INDICATIONS FOR THE FUTURE 
Further research is needed to fill in the many 
gaps that exist in the field of diagnosis in dermatol-
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FIG. 2. Eluate from the peripheral lymphocytes of a 
patient with psoriasis vulgaris with FTC-labeled antihu-
man IgD to show positive immunofluorescence of the 
nuclei of the basal cell layer of the uninvolved skin of the 
same patient. 
ogy. Some of the most obvious gaps are listed 
below. 
1. Various approaches must be used to detect 
the antigen responsible for the disease state and to 
uncover the etiology of many diseases. 
2. More accurate methods of detecting immune 
complexes must be found. 
3. More studies are needed on the components 
of the alternative pathways of complement activa-
tion and their involvement in disease states. Pro-
duction of antibodies against all of them will 
enable us to estimate them quantitatively. 
4. Further studies must be done on the anti-
bodies coated on ancillary cells. 
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